State Street Corp Raises Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

State Street Corp raised its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 4.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 71,408 shares of the company’s stock after acquiring an additional 3,005 shares during the period. State Street Corp owned approximately 0.54% of Greenwich LifeSciences worth $1,026,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Garden State Investment Advisory Services LLC purchased a new stake in shares of Greenwich LifeSciences during the 3rd quarter worth about $253,000. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences during the second quarter valued at approximately $264,000. Finally, Rhumbline Advisers purchased a new stake in Greenwich LifeSciences during the second quarter worth approximately $117,000. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Greenwich LifeSciences Stock Up 4.5 %

Greenwich LifeSciences stock opened at $11.74 on Friday. The firm has a fifty day moving average of $13.25 and a 200-day moving average of $14.24. Greenwich LifeSciences, Inc. has a 52-week low of $8.00 and a 52-week high of $21.44. The firm has a market capitalization of $154.32 million, a P/E ratio of -14.67 and a beta of 1.61.

Insider Buying and Selling

In related news, CEO Snehal Patel acquired 3,200 shares of Greenwich LifeSciences stock in a transaction on Monday, December 30th. The shares were bought at an average price of $11.12 per share, for a total transaction of $35,584.00. Following the completion of the purchase, the chief executive officer now directly owns 5,539,302 shares in the company, valued at $61,597,038.24. This trade represents a 0.06 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 51.67% of the stock is owned by corporate insiders.

Greenwich LifeSciences Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.